Abstract

In response to the current COVID-19 pandemic, it is of paramount importance to rapidly diagnose infections and to develop countermeasures. This project aims to build a high-throughput platform for rapid COVID-19 serodiagnosis, vaccine evaluation, and therapeutics development.

Public Health Relevance

The ongoing SARS-CoV-2 has caused global pandemic. Rapid response to disease control and countermeasure development is a public health priority. The development of a high-throughput platform is a top priority for rapid COVID-19 serodiagnosis, vaccine, and antiviral R&D.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI134907-03S2
Application #
10142203
Study Section
Program Officer
Dupuy, Lesley Conrad
Project Start
2020-05-01
Project End
2021-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
University of Texas Med Br Galveston
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555

  Publications

Bharaj, Preeti; Atkins, Colm; Luthra, Priya et al. (2017) The Host E3-Ubiquitin Ligase TRIM6 Ubiquitinates the Ebola Virus VP35 Protein and Promotes Virus Replication. J Virol 91:
van Tol, Sarah; Hage, Adam; Giraldo, Maria Isabel et al. (2017) The TRIMendous Role of TRIMs in Virus-Host Interactions. Vaccines (Basel) 5: